Giganti F, et al. - The goal of the study was to explore changes in the Apparent Diffusion Coefficient (ADC) utilizing diffusion-weighted imaging (DWI) in men on active surveillance for prostate cancer taking dutasteride (0.5 mg) or placebo. It was shown that the dutasteride was related to increased tumour ADC and decreased conspicuity. It was also noted that a lower threshold for triggering biopsy might be considered in men on dutasteride undergoing mpMRI for prostate cancer.